fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Roche provides update on phase III Ocrevus (ocrelizumab) high dose study in people with relapsing multiple sclerosis

Written by | 8 May 2025

Roche announced that the Phase III MUSETTE trial comparing a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in… read more.

Investigational tolebrutinib shows efficacy for non-relapsing secondary progressive multiple sclerosis (SPMS)

Written by | 12 Apr 2025

Results from a Phase 3 study of treatment with investigational tolebrutinib show a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing… read more.

AI tool can track effectiveness of multiple sclerosis treatments

Written by | 11 Apr 2025

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL… read more.

High fish intake linked to slower disability progression in MS

Written by | 27 Feb 2025

High intake of lean and oily fish appears to slow the progression of disability in multiple sclerosis (MS), researchers reported on Feb. 25, 2025 in the Journal of Neurology… read more.

MS raises risk of mental illness during and soon after pregnancy

Written by | 23 Jan 2025

Women diagnosed with multiple sclerosis (MS) have a significantly higher risk of developing mental illness during pregnancy and soon after birth compared to women who become pregnant while… read more.

Most MS therapies not associated with worst pregnancy outcomes

Written by | 31 Dec 2024

Researchers report that most treatments for pregnant women with MS (multiple sclerosis) do not lead to increased risks of major adverse outcomes. “We found that most therapies were… read more.

MS not associated with COVID-19 relapse after vaccination

Written by | 15 Aug 2024

People with multiple sclerosis (MS) do not appear to be at an increased risk of relapse after COVID-19 vaccination, researchers reported on August 14, 2024 in Neurology. “People… read more.

MHRA (UK) has approved the subcutaneous version of Ocrevus to treat patients with relapsing and primary progressive multiple sclerosis – Roche

Written by | 19 Jul 2024

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche’s subcutaneous version of Ocrevus (ocrelizumab subcutaneous ) to treat patients with relapsing and primary progressive… read more.

Kesimpta (ofatumumab) six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis – Novartis

Written by | 20 Apr 2024

Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability… read more.

MHRA (UK) extends indication of Mavenclad (cladribine tablets) for relapsing forms of multiple sclerosis – Merck KGaA

Written by | 3 Apr 2024

Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by… read more.

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko (natalizumab) in Germany

Written by | 5 Feb 2024

Sandoz announces the launch of Tyruko (natalizumab) in Germany from February Developed by Polpharma Biologics, Tyruko is the first and only biosimilar to treat RRMS.(r/r Multiple Sclerosis). Tyruko… read more.

Vanda Pharmaceuticals acquires U.S. and Canadian rights to Ponvory (ponesimod), a selective S1P1R modulator, approved for patients with relapsing multiple sclerosis

Written by | 15 Dec 2023

Vanda Pharmaceuticals Inc. announced that it has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. Ponvory is approved… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.